Brian F. Chapin MD, FACSAssociate Professor of Urology; Director, Fellowship Program in Urologic Oncology; Co-Director, Clinical Research Programs, University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Brian Chapin is an Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center. He provides complete surgical care for men and women diagnosed with urologic malignancies. He performs open surgery and minimally invasive/robotic surgery, for patients with prostate, kidney, bladder and testis cancers. His major clinical focus is on the treatment of high risk- localized, locally advanced and metastatic prostate cancers. He has active clinical research protocols developing the integration of surgical, radiation and medical therapies in the treatment of advanced prostate cancer. Dr. Chapin is involved with the basic science/translational research program at M.D Anderson, which is attempting to identify predictive signatures for identifying which patients with advanced prostate cancer will benefit most from specific therapies. Using a comprehensive multimodality approach to this disease, Dr. Chapin’s goal is to ease suffering and prolong survival in men with advanced prostate cancer.
2018 – present: Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
2016 – present: Fellowship Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
2016 – present: Co-Director of Clinical Research Programs, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center
DisclosuresDr. Chapin reports the following:
- Research Funding – Janssen Pharmaceuticals
- Consulting/Advisory Board – Janssen Pharmaceuticals and Blue Earth Diagnostics
Recent Contributions to PracticeUpdate:
- Implementation of Germline Testing for Prostate Cancer
- Effect of Chemotherapy With Docetaxel and Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
- Adjuvant Radiation With ADT for Men With Lymph Node Metastases After Radical Prostatectomy
- Extensive Lymph Node Dissection at Radical Prostatectomy Is Associated With Improved Outcomes With Salvage Radiotherapy for Rising PSA After Surgery
- Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients With Low-Volume Bone Metastasis?
- Survival Improves in Newly Diagnosed Metastatic Prostate Cancer With Prostate Radiation Added to ADT